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Abstract  30 
E11/Podoplanin (Pdpn) is implicated in early osteocytogenesis and the formation of osteocyte 31 
dendrites. This dendritic network is critical for bone modeling/remodeling, through the 32 
production of the receptor for receptor activator of nuclear factor κB (RANK)-ligand 33 
(RANKL). Despite this, the role of Pdpn in the control of bone remodeling is yet to be 34 
established in vivo. Here we utilised bone-specific Pdpn conditional knockout mice (cKO) to 35 
examine the role of Pdpn in the bone loss associated with ovariectomy (OVX). MicroCT 36 
revealed that Pdpn deletion had no significant effect on OVX-induced changes in trabecular 37 
microarchitecture. Significant differences between genotypes were observed in the trabecular 38 
pattern factor (P<0.01) and structure model index (P<0.01). Phalloidin staining of F-actin 39 
revealed OVX to induce alterations in osteocyte morphology in both wild-type and cKO 40 
mice. Histological analysis revealed an expected significant increase in osteoclast number in 41 
wild-type mice (P<0.01, compared to sham). However, cKO mice were protected against 42 
such increases in osteoclast number. Consistent with this, serum levels of the bone resorption 43 
marker Ctx were significantly increased in wild-type mice following OVX (P<0.05), but 44 
were unmodified by OVX in cKO mice. Gene expression of the bone remodeling markers 45 
Rank, Rankl, Opg and Sost were unaffected by Pdpn deletion. Together, our data suggest that 46 
an intact osteocyte dendritic network is required for sustaining osteoclast formation and 47 
activity in the estrogen-deplete state, through mechanisms potentially independent of 48 
RANKL expression. This work will enable a greater understanding of the role of osteocytes 49 
in bone loss induced by estrogen deprivation. 50 
 51 
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Introduction 61 
Throughout life our skeleton is continuously remodeled, a process which is under tight 62 
regulation so as to ensure an imbalance in bone formation or bone resorption does not occur. 63 
Such imbalance in favour of bone resorption results in pathological bone loss leading to 64 
osteopenia and osteoporosis. These diseases dramatically enhance risk of fracture and as 65 
such, are a massive worldwide healthcare burden.
 
66 
Osteoclasts are responsible for the resorption of mineralized bone through the release of 67 
protons for mineral dissolution and enzymes, such as tartrate-resistant acid phosphatase 68 
(TRAP) and members of the cathepsin and matrix metalloproteinase (MMP) families for the 69 
degradation of the organic bone matrix.
1
 Osteoclasts originate from a hemopoietic lineage 70 
and their differentiation is stimulated by macrophage colony-stimulating factor (M-CSF), and 71 
receptor for activation of nuclear factor κ B (RANK) ligand (RANKL). Despite their 72 
opposing functional roles, compelling evidence supports a pivotal role for osteoblasts in the 73 
regulation of osteoclast differentiation.
2 
More recently, evidence has also implicated a critical 74 
role for the osteoblast-derived osteocyte in the regulation of osteoclast differentiation via the 75 
production of RANKL.
3,4
 Indeed the selective conditional deletion of RANKL in osteocytes 76 
resulted in a marked osteopetrotic phenotype in skeletally mature mice.
4
  77 
Osteocytes are the most abundant cell type of the adult skeleton. It has long been considered 78 
that osteocytes are formed by the passive entrapment of redundant osteoblasts by osteoid 79 
synthesized by their close neighbors.
5,6
 The transition from the cuboidal-like osteoblastic 80 
morphology to a dendritic shape characteristic of an osteocyte is however a more active and 81 
tightly regulated process than was originally recognized.
7,8
 The characteristic dendritic 82 
phenotype enables the osteocyte to form a highly connected syncytium with neighbouring 83 
osteocytes and surface osteoblasts and osteoclasts, and places the osteocyte at the centre of 84 
bone modeling/remodeling regulatory pathways (for reviews see 
9,10
). 85 
We, and others, have previously highlighted the requirement for the transmembrane 86 
glycoprotein E11/podoplanin (Pdpn) to make the cytoskeletal network modifications that are 87 
critical for the formation of dendrites during osteocytogenesis. This role is consistent with its 88 
expression by early embedding osteocytes, thus identifying Pdpn as a factor which likely 89 
contributes to the vital, early stages of osteocyte differentiation.
11
 Furthermore, Pdpn 90 
expression in osteocytes is increased in response to mechanical strain in vivo
12
 and the 91 
formation of dendritic processes is promoted by both Pdpn overexpression and through its 92 
stabilisation by proteasome inhibitors.
11,13
 In contrast, the formation of these cytoplasmic 93 
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processes is abrogated in cells pre-treated with siRNA targeted against Pdpn and in mice with 94 
a bone specific ablation of Pdpn.
14 
From this evidence, it is reasonable to conclude that Pdpn 95 
has an important functional role in the formation of dendritic processes which are a key 96 
feature of the differentiating osteocyte. Nonetheless, important gaps remain in our 97 
understanding of the essential role played by Pdpn in full osteocyte function; in particular the 98 
control of osteoblast and osteoclast actions during the bone remodeling process.  99 
Global deletion of Pdpn is perinatally lethal due to the essential role of Pdpn in lung and 100 
epithelial cell function.
12
 Therefore, in order to test our working hypothesis that Pdpn drives 101 
osteocytogenesis and thus regulates bone remodeling, we have utilised our previously 102 
characterized osteocalcin-Cre driven bone specific Pdpn hypomorphic deletion in mice
14
 103 
(cKO) to compare the effects of ovariectomy (OVX)-induced bone loss in cKO to wild-type 104 
(WT) mice.  105 
Materials and Methods 106 
Animals   107 
Bone specific Pdpn conditional hypomorphic knockout mice (cKO; ~70% reduction in 108 
protein Pdpn expression) were generated as previously described under the control of the 109 
osteocalcin (OC)-Cre promotor.
14
 OC-Cre mice (WT) were used as controls. Mice were kept 110 
in polypropylene cages, with light/dark 12-h cycles, at 21 ± 2°C, and fed ad libitum with 111 
maintenance diet (Special Diet Services, Witham, UK). All experimental protocols were 112 
approved by Roslin Institute's Animal Users Committee (A650) and experiments were 113 
conducted at the Roslin Institute, University of Edinburgh. Animals were maintained in 114 
accordance with UK Home Office guidelines for the care and use of laboratory animals. 115 
OVX model of enhanced bone remodeling 116 
At ten weeks of age, female cKO and WT mice were subjected to either OVX (n=6/genotype) 117 
or sham operation (n=6/genotype), with isoflurane anaesthesia. Tissues were collected 4 118 
weeks post-surgery (14 weeks of age) following exsanguination under terminal anaesthesia. 119 
Uterine and body weight were assessed at sacrifice.  120 
Histological analysis 121 
Right femora were fixed for 24 hours in 4% formaldehyde in phosphate buffered saline (PBS) 122 
and stored in 70% ethanol. Samples were decalcified in 10% ethylenediaminetetraacetic acid 123 
(EDTA) for 21 days at 4
o
C, with the solution changed every 4-5 days. Samples were washed 124 
in PBS, bisected in the sagittal plane, processed to paraffin wax using a Leica (Wetzlar, 125 
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Germany) ASP300S Tissue Processor, and embedded in wax on the medial cut surface. A 126 
Leica rotary microtome was used to cut 3µm sections which were mounted on Superfrost 127 
glass slides (Thermo Fisher Scientific, USA). Slides were stained with H&E and Goldner’s 128 
Trichrome using standard protocols. For TRAP staining 70mg napthol AS-TR phosphate 129 
(Sigma) was dissolved in 250µl N-N dimethyl formamide (Sigma) and added to 50ml 0.2M 130 
sodium acetate buffer pH5.2. 115mg sodium tartrate dihydrate (Sigma) and 70mg fast red salt 131 
TR (Sigma) was dissolved into this solution and slides were incubated at 37
o
C for 2 hours. 132 
Sections were counterstained in Meyer’s haematoxylin (Sigma), washed in distilled water and 133 
mounted in aqueous mounting medium (Vector Labs). Slides were imaged using a 134 
NanoZoomer XR slide scanning system (Hamamatsu Photonics, Japan). Histomorphometry 135 
was performed using the BIOQUANT OSTEO (BIOQUANT Image Analysis Corporation, 136 
Texas, USA) software package using the approved ASBMR histomorphometry nomenclature 137 
(3 sections/mouse; WT sham n=6, WT OVX n=5, cKO sham n=6, cKO OVX n=4).15  138 
Phalloidin staining  139 
Wax embedded 10µm sections were washed in PBS twice for 5 min each, and incubated with 140 
0.1% Triton-X 100 (Sigma–Aldrich) for 30 min and then rinsed with PBS. Slides were then 141 
incubated with Alexa Fluor 488-conjugated phalloidin (1:500; Abcam, Cambridge, UK) for 1 142 
hr. Bone sections were washed in PBS and mounted in ProlongGold (Thermo Fisher 143 
Scientific, USA). Preparations were allowed to dry at room temperature for 12 hr. Optical 144 
sections were taken using the LSM 880 Airyscan confocal laser scanning microscope using 145 
the 488 nm laser excitation and detection settings from 493 nm to 634 nm. Z-stacks were 146 
produced with optimal Nyquist overlap settings using a 63×/1.4na oil immersion lens. Voxel 147 
sizes were 0.043 × 0.043 × 0.5 μm in x,y,z planes respectively. A comparable region of 148 
interest was analyzed for osteocyte parameters in all samples located in the diaphyseal 149 
cortical bone. Image stacks were imported into Bitplane Imaris 9.3.0 software and algorithms 150 
were created with Imaris FilamentTracer to render and measure dendritic processes. Surface 151 
rendering was used for osteocyte cell body measurements.  152 
Micro-computed tomography analysis (µCT) 153 
Right tibiae were dissected and frozen at -20
o
C in dH2O until required. The laboratory scans 154 
were performed with a 1172 X-Ray Microtomograph (Bruker, Belgium) to evaluate the 155 
epiphyseal trabecular bone microarchitecture. High-resolution scans with an isotropic voxel 156 
size of 5 µm were acquired (50 kV, 0.5 mm aluminium filter, 0.6° rotation angle, 2 frame 157 
averaging). The scans were reconstructed using NRecon software (Bruker) and filters were 158 
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applied to the images prior to reconstruction to remove artefacts, including beam-hardening 159 
and ring artefacts. A 1000 µm section of the metaphysis 250 µm subjacent to the growth plate 160 
was taken for analysis of trabecular bone. A 500 µm section of the mid-diaphysis, 3735 µm 161 
subjacent to the growth plate, was segmented for analysis of cortical structure. Data was 162 
analyzed with CtAn software (Bruker). To assess bone mineral density (BMD), BMD 163 
phantoms of known calcium hydroxyapatite mineral densities of 0.25 and 0.75 g/cm
3
 were 164 
used.   165 
Serum markers of bone formation and resorption  166 
Blood samples from WT and cKO mice were obtained by cardiac puncture under terminal 167 
anaesthesia and serum samples were prepared by centrifugation at 1000 x g for 10 min at 168 
4
o
C. Markers of bone formation (P1NP) and bone resorption (Ctx) were quantified by ELISA 169 
according to the manufacturer’s instructions (AMS Biotechnology, Abingdon, UK).   170 
RNA extraction and quantitative real-time PCR 171 
Left femurs had their marrow removed by centrifugation before being homogenized in Qiazol 172 
reagent (Qiagen) and total RNA was extracted using an RNeasy mini lipid kit (Qiagen), 173 
according to the manufacturer’s instructions. Reverse transcription was completed using 174 
Superscript II reverse transcriptase (Invitrogen) and gene expression analysis was carried out 175 
by RT-qPCR performed on a Stratagene Mx3000P real-time qPCR machine (Stratagene, 176 
Santa Clara, USA) using PrecisionPlus qPCR masterimix with SYBRgreen (Primer Design, 177 
Southampton, UK). Relative gene expression was calculated using the ΔΔCt method.16 Each 178 
cDNA sample was normalized to the housekeeping gene Gapdh (sequences not disclosed; 179 
Primer Design). Reactions were performed with gene-of-interest primers (5′-3′): Rankl 180 
(Tnfsf11) F - CGCCAACATTTGCTTTCGG  R - TTTTAACGACATACACCATCAGC ; 181 
Opg (Tnfrsf11b): F – AAATTGGCTGAGTGTTTTGGTG R - 182 
CTGTGTCTCCGTTTTATCCTCTC; Sost: F – TGAGAACAACCAGACCATGAAC R - 183 
TCAGGAAGCGGGTGTAGTG (Primer Design) and Rank (Tnfrsf11a): F – 184 
GCGCAACAGTGTTTCCACAG R – CGCTTGGATCACAGTAAGGCT (Merck).  185 
Statistical analysis 186 
Data were analyzed by one-way analysis of variance, Student’s t-test, or a suitable 187 
nonparametric test using GraphPad Prism 6 and following normality checks. Data are 188 
expressed as the mean ± S.E.M. Results were analyzed blinded.  P<0.05 was considered to be 189 
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significant and noted as *; P values of <0.01 and <0.001 were noted as ‘**’ and ‘***’ 190 
respectively.  191 
Results 192 
OVX of Pdpn cKO and WT mice 193 
Ten-week old WT and cKO mice were subjected to either OVX or sham surgeries. To 194 
evaluate the efficacy of the surgery, uterine weights were examined 4-weeks post-surgery. 195 
The effect of OVX was similar in both the cKO and the WT, with both genotypes exhibiting 196 
a 30-40% reduction (p<0.001) in uterine weight in comparison to the sham operated mice 197 
(Fig. 1A). Interestingly the uterine weight of the sham operated cKO mice was higher than 198 
the equivalent control mice (P<0.05). No differences were observed in the total body weight 199 
between genotypes and/or surgeries (Fig. 1B). These results confirm the success of the OVX 200 
and that the hypomorphic deletion of Pdpn does not modify the uterine response to decreased 201 
estrogen.  202 
Bone microarchitecture changes in response to OVX with Pdpn deletion 203 
OVX caused modest changes to the trabecular microarchitecture of cKO and WT mice 204 
compared to their equivalent sham operated control mice. Trabecular BV, trabecular number 205 
and trabecular thickness were all slightly diminished four weeks post-OVX in both genotypes 206 
and, although apparently more marked in cKO mice, these changes did not reach statistical 207 
significance (Fig. 2A-E). A significant difference between genotypes was observed in the 208 
trabecular pattern factor (P<0.05; Fig. 2G), indicating a more markedly disconnected 209 
trabecular structure in the Pdpn cKO mice than in WT mice following OVX (P<0.01; Fig. 210 
2G). This correlates closely with the structure model index which was also significantly 211 
increased in Pdpn cKO mice with OVX (P<0.01; Fig. 2H). No effects of genotype or OVX 212 
were observed in trabecular BMD (Fig. 2I). Cortical bone analysis indicated a significant 213 
decrease in BV/TV in WT mice with OVX (P<0.01), however no effect was observed in 214 
Pdpn cKO mice (Suppl. Fig. S1). A modest decrease in cross-sectional thickness was also 215 
observed with OVX in WT mice, and this was significantly decreased in Pdpn cKO mice 216 
(P<0.05; Suppl. Fig. S1). No significant differences were observed in other cortical bone 217 
parameters (Suppl. Fig. S1). 218 
OVX induces alterations in osteocyte morphology in WT and Pdpn cKO mice 219 
To further delineate the association between Pdpn and osteocyte formation with OVX, we 220 
next performed phalloidin staining of F-actin in WT and cKO cortical bone. Subsequent 3D 221 
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rendering and quantitative analysis of osteocytes confirmed our previously published data: 222 
modest decreases in the total number of cell bodies (Fig. 3A) and the total number of 223 
dendrites (Fig. 3C), and significant decreases in cell body volume (P<0.001; Fig. 3B), and 224 
dendrite length (P<0.05; Fig. 3D) in sham-operated cKO mice compared to WT were 225 
observed. Interestingly, a significant increase in dendrite volume was noted in cKO mice 226 
compared to WT (P<0.05, Fig. 3E). In WT mice, OVX significantly increased the cell body 227 
volume (P<0.01; Fig. 3B) and dendrite volume (P<0.001; Fig. 3E). Similar trends were seen 228 
in cKO mice with OVX, with significant increases in cell body volume (P<0.001; Fig. 3B) 229 
and dendrite length (P<0.001; Fig. 3D) observed.  230 
Gene expression of bone remodeling markers are unaffected by hypomorphic deletion of 231 
Pdpn 232 
The RANK/RANKL/osteoprotegrin (OPG) axis is major influence on bone remodeling and if 233 
the RANKL/OPG ratio becomes imbalanced then osteopenia can result. Therefore we 234 
examined whether OVX-related changes in the expression of Opg, Rankl and Rank were 235 
affected by Pdpn deletion. Although trends were seen for increased Rankl and Opg 236 
expression in OVX mice, no statistically significant differences were observed between WT 237 
and cKO mice (Fig. 4A & B). Similarly, no significant differences were observed in the 238 
expression of Rank (Fig. 4C), and changes the Rankl/Opg ratio in response to OVX were 239 
similar in WT and cKO mice (Fig. 4D). Sclerostin is a negative regulator of Wnt signaling 240 
and bone formation and is down regulated in bones from OVX mice. However, in this present 241 
study we noted that although this increase did not reach significance, Sost expression was 242 
somewhat raised by OVX in both WT and cKO mice (Fig. 4E). 243 
Deletion of Pdpn protected against increased osteoclast numbers with OVX 244 
Histological assessment of TRAP activity in WT mice following sham and OVX surgeries 245 
revealed an expected significant increase in osteoclast number per bone surface upon OVX 246 
surgery (P<0.01 in comparison to sham operated WT mice; Fig. 5A & B). In contrast, the 247 
cKO mice appeared to be protected from the OVX-induced increase in osteoclast number, 248 
which instead was similar in OVX and sham-operated cKO mice (Fig. 5A & B). A significant 249 
difference in osteoclast number per bone surface was also observed between WT and cKO 250 
OVX mice (P<0.05; Fig. 5B). Serum levels of the resorption marker Ctx were also 251 
significantly increased in WT mice following OVX surgery but remained unchanged in cKO 252 
mice following OVX surgery (Fig. 5D). In contrast, both osteoblast number (Fig. 5C) and 253 
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serum P1NP, a marker of bone formation, were unaffected by OVX surgery and were similar 254 
in WT and cKO OVX mice (Fig. 5E).  255 
Discussion 256 
This manuscript utilised our previously characterised Pdpn cKO mice to examine the effects 257 
of OVX-induced bone resorption in an attempt to decipher the in vivo role of Pdpn on the 258 
bone remodeling process.
14
 Here we found that whilst the hypomorphic deletion of Pdpn had 259 
no marked effect on OVX-induced bone phenotype, at the time point studied it protected 260 
against OVX-related increases in osteoclast number and the Ctx marker of bone resorption.    261 
The vast osteocyte dendritic network is critical to cell-cell communication in bone, 262 
maintaining cell viability and allowing the transfer of nutrients and waste products.
10
 We and 263 
others have previously shown that Pdpn promotes osteocytogenesis and dendrite formation in 264 
vitro.
11,12
 Similarly, we have previously shown that stabilisation of Pdpn protein, through 265 
inhibition of endogenous targeted proteasome activity, promotes dendrite formation in vitro.
11
 266 
By using the cre-LoxP system targeted to exon 3 of the Pdpn gene, we have recently 267 
generated bone specific (OC-Cre) conditional knockdown mice. We revealed that whilst 268 
Pdpn deletion did not affect osteocyte differentiation in vivo, a vital role for Pdpn in the 269 
formation of full length dendritic processes was observed.
14
 Here, our data confirm this and 270 
suggest that the hypomorphic deletion of Pdpn and the subsequent inadequate dendrite 271 
formation, quantified by phalloidin staining for F-actin, does not affect OVX-induced 272 
changes in the trabecular bone microarchitecture. Interestingly a modest increase in the total 273 
number of dendrites was observed in cKO mice upon OVX and this therefore may have 274 
influence on the ability to respond to skeletal load, but its relevance to the regulation of bone 275 
remodelling needs further investigation. 276 
Numerous studies have reported the detrimental effects of estrogen deficiency on osteocyte 277 
viability. Indeed, estrogen maintains osteocyte viability and its depletion in OVX results in 278 
regional osteocyte apoptosis in animal models and in human bone biopsies.
17–19
 Inhibition of 279 
osteocyte apoptosis through administration of the pan-caspase inhibitor QVD prevented 280 
increases in the osteoclastic resorption normally observed with OVX, thus suggesting a key 281 
role for osteocyte apoptosis in the initiation of endocortical remodelling in response to 282 
estrogen deficiency.
19
 Consistent with this, here we observed modest yet non-significant 283 
decreases in the total number of osteocyte cell bodies with OVX in WT mice. Therefore, 284 
future studies examining the viability of the osteocytes in our model would be of great 285 
interest. In particular, it would be interesting to see if our cKO mice exhibit decreased 286 
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osteocyte apoptosis and hence are protected against OVX-induced increases in osteoclast 287 
activity.          288 
Osteocytes play an integral role in maintaining bone homeostasis by regulating bone 289 
modeling and remodeling through communicating with bone-resorbing osteoclasts via 290 
RANKL production.
3,4
 Osteoclasts are specialized multinucleated cells that arise from bone 291 
marrow precursors and their differentiation is promoted by RANKL. Indeed the targeted 292 
disruption of RANKL in mice results in severe osteopetrosis.
3,20
 OVX in mice stimulates 293 
bone resorption by increasing osteoclast formation and activity due to decreased estrogen 294 
levels as is seen in women with postmenopausal osteoporosis. Here we observed expected 295 
increases in osteoclast number in WT mice subjected to OVX. However, Pdpn cKO mice 296 
exhibited a protection against OVX-induced increases in osteoclast number as well as 297 
activity, as indicated by TRAP activity and serum levels of the bone resorption marker Ctx, 298 
respectively. This could be due, in part, to the known disruption to the osteocyte dendritic 299 
network previously reported in Pdpn cKO mice
14
 and thus infer a decreased capacity to 300 
promote osteoclastogenesis through ineffective RANKL production by osteocytes lacking 301 
Pdpn. Our gene expression data suggested that no significant differences were observed in 302 
RANKL in either WT or Pdpn cKO mice, however this may be due to RANKL expression 303 
not being exclusive to osteocytes. Indeed RANKL can be produced by stromal cells, 304 
osteoblasts, T lymphocytes, and B lymphocytes in bone.
21
 Furthermore, it has been reported 305 
that osteoblasts are the major source of RANKL during estrogen deficiency and thus suggest 306 
that the lack of changes in RANKL expression which we observe are independent of the 307 
osteocyte network.
22
 A focus in future studies could be to further delineate this source of 308 
RANKL and could correlate changes in gene expression to that of protein expression for 309 
example through immunohistochemical labelling.  310 
Compelling evidence for a role for osteocytes in regulating bone remodeling also comes from 311 
the discovery that osteocytes, deep in calcified bone, produce sclerostin, a Wnt inhibitor and 312 
potent negative modulator of bone formation.
23–25
 Indeed, sclerostin has been implicated as a 313 
regulator of the differentiation from late osteoblast to pre-osteocyte, which antagonizes Wnt 314 
signalling through binding to the Wnt co-receptors, low-density lipoprotein receptor-related 315 
proteins 5 and 6 (LRP5 and LRP6), thereby leading to β-catenin phosphorylation and 316 
subsequent degradation.
26
 The therapeutic potential of targeting sclerostin has recently been 317 
exploited as an anabolic treatment for osteoporosis.
27–30
 Here we observed trends towards 318 
increases in bone sclerostin mRNA expression in response to OVX, however, these trends 319 
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failed to reach levels of statistical significance and no differences were observed between 320 
genotypes. This is consistent with our previous study in which we observed that the 321 
hypomorphic deletion of Pdpn exerted no effect on sclerostin levels in vivo, and failed to 322 
modify osteocyte number, shape or size in these mice.
14
  323 
In summary, our data confirm a role for Pdpn in OVX-induced bone remodeling and that an 324 
intact osteocyte network contributes to increases in osteoclastogenesis in OVX-induced bone 325 
loss, through mechanisms potentially independent of RANKL expression. This work will 326 
enable a greater understanding of role of osteocytes in bone loss induced by estrogen 327 
deprivation. 328 
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Figure legends 424 
Figure 1. Effects of OVX on WT and Pdpn cKO mice. (A) Uterine weight (g) (B) Total 425 
body weight (g). Data are presented as mean ± S.E.M for n≥4; ***p<0.001.  426 
Figure 2. Effects of OVX on WT and Pdpn cKO mouse trabecular bone 427 
microarchitecture. Micro-CT analysis of tibia trabecular microarchitecture in WT and Pdpn 428 
cKO mice in response to OVX (A) Tb. TV (Trabecular tissue volume; mm
3
) (B) Tb. BV 429 
(Trabecular bone volume; mm
3
) (C) Tb. BV/TV (Trabecular BV/TV; %) (D) Tb. N. 430 
(Trabecular Number; mm
-1
) (E) Tb. Th. (Trabecular thickness; mm) (F) Tb. Sp. (Trabecular 431 
Separation; mm) (G) Tb. Pf. (Trabecular Pattern Factor; mm
-1
) (H) SMI (Structure model 432 
index) (I) BMD (Bone mineral density; g/cm
3
). (J) Representative images. Data are presented 433 
as mean ± S.E.M for n≥5; **p<0.01.  434 
Figure 3. Osteocyte morphology in WT and Pdpn cKO mouse bone. Quantification of 435 
osteocyte morphology parameters using phalloidin-Factin staining and 3D rendering (A) 436 
Total number of complete cell bodies / cm
3. (B) Cell body volume (μm3) (C) Total number of 437 
dendrites / cm
3
 (D) Dendrite length (μm) (E) Dendrite volume (μm3). Data are represented as 438 
mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 439 
Figure 4. Gene expression in WT and Pdpn cKO mouse bone. RT-qPCR analysis of (A) 440 
RANKL (Tnfsf11) (B) OPG (Tnfrsf11b) (C) RANK (Tnfrsf11a) (D) RANKL:OPG ratio (E) 441 
sclerostin (Sost). Data are presented as mean ± S.E.M for n≥5. 442 
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Figure 5. Effects of OVX on WT and Pdpn cKO mouse bone histology. (A) 443 
Representative micrographs of WT and cKO tibiae following sham or OVX surgery, 20X 444 
magnification. Osteoclasts marked with black arrowheads. Histological analysis of cell 445 
counts in sham vs OVX bones: (B) Number of osteoclasts / bone surface. (C) Number of 446 
osteoblasts / bone surface. (D) Concentration of Ctx (marker of bone resorption) (E) 447 
Concentration of P1NP (bone formation). Data are presented as mean ± S.E.M for n≥5; 448 
*P<0.05. Scale bars represent 200µm. 449 
Suppl. Fig. 1. Effects of OVX on WT and Pdpn cKO mouse cortical bone geometry. 450 
Micro-CT analysis of tibia cortical bone geometry in WT and Pdpn cKO mice in response to 451 
OVX (A) TV (cortical tissue volume; mm
3
) (B) BV (cortical bone volume; mm
3
) (C) BV/TV 452 
(bone volume/tissue volume; %) (D) Cs. Th. (Cross-sectional thickness; mm) (E) T. Ar. 453 
(Mean total cross-sectional tissue area; mm
2
) (F) T. Pm. (Mean total cross-sectional tissue 454 
perimeter; mm) (G) Bone Ar. (Mean total cross-sectional bone area; mm
2
) (H) Bone Pm. 455 
(Mean total cross-sectional bone perimeter; mm) (I) MMI (Mean polar moment of inertia; 456 
mm
4
). (J) Representative images. Data are presented as mean ± S.E.M for n≥5; **p<0.01.  457 
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